Aptahem enters into an agreement with Yorkville Advisors Global securing financing of up to MSEK 20

2018-06-27

Aptahem AB (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved in the disease process, today announce its entry into an issuance agreement with...

Read More

Aptahem and Seattle Children’s Research Institute partner to study experimental sepsis drug

2018-06-13

Aptahem AB (publ) announces a partnership with Seattle Children’s Research Institute to explore the mechanisms underlying their new aptamer-based therapeutic for acute and chronic inflammatory conditions including sepsis. Sepsis is a complex and potentially life-threatening condition that occurs when...

Read More